Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mexico And Brazil Release Biosimilars Guidelines, But Not All Issues Resolved

This article was originally published in PharmAsia News

Executive Summary

Mexico published its final biosimilars guidelines the same day as India, both drawing from WHO standards.

You may also be interested in...



Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News

Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan

Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., E.U. Markets

BEIJING - Flush with cash from expanding earnings, leading Chinese biotech outfit 3SBio is scanning the globe for promising in-licensing deals to complement its in-house drug development pipeline and is exploring the potential to one day enter the biosimilars markets in the United States and the European Union

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel